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Remote Ischemic Preconditioning
A Novel Strategy in Rescuing Older Livers from Ischemia-reperfusion Injury
in a Rodent Model
Perparim Limani, MD, Michael Linecker, MD, Christian E. Oberkofler, MD, Gery Barmettler,y
Andres Kaech, PhD,y Rolf Graf, PhD, Bostjan Humar, PhD, and Pierre-Alain Clavien, MD, PhD
Objectives: The aim of this study was to determine whether remote ischemic
preconditioning (RIPC) protects aged liver against ischemia reperfusion (IR).
Summary of Background Data: The demands for liver surgery in an aging
population are growing. Clamping of vessels to prevent blood loss is integral
to liver surgery, but the resulting IR injury (IRI) augments postoperative
complications. More so, sensitivity to hepatic IRI increases with age; how-
ever, no strategies have been developed that specifically protect old liver.
RIPC, a novel protective approach, was performed distant to the surgical site.
Whether RIPC may also protect old liver from IRI is unknown.
Methods: RIPC to the femoral vascular bundle was compared against direct
ischemic preconditioning (IPC) and the standard of care intermittent clamping
(IC) using a model of partial hepatic ischemia in mice aged 20 to 24 months.
Liver injury was measured 6 hours after reperfusion. Protective signaling
(serotonin-Vegf-Il10/Mmp8 axis, Kupffer cell polarization) was assessed
immediately after preconditioning. Neutralizing antibody was used to test
the role of Vegf. Hepatic vasculature was examined by electron microscopy.
Results: RIPC was superior over other strategies in protecting old liver from
IRI, with standard IPC approaches being ineffective. RIPC induced the
strongest elevations in circulating Vegf, and Vegf inhibition dampened
protective signaling and abrogated the protective effects. RIPC was further
associated with improvements in vascular functionality.
Conclusions: RIPC is highly effective in protecting old liver from ischemic
insults, mainly owing to its ability to induce circulating Vegf. These findings
warrant efforts toward clinical translation.
Keywords: intermittent clamping, ischemia reperfusion injury, old liver,
remote ischemic preconditioning
(Ann Surg 2016;xx:xxx–xxx)
I schemia and reperfusion injury (IRI) represents a significantsource of morbidity and mortality after liver surgery.1 Limitation
of blood supply – to minimize blood loss during liver parenchyma
transection – followed by restoration of perfusion induces an exag-
gerated inflammatory reaction that eventually leads to neutrophil-
mediated destruction of liver tissue.2 Tomitigate ischemic insults and
associated postoperative complications, several protective measures
have been developed.3,4 Although these measures are being used in
the clinic,5–8 their efficacy in old liver has never been explicitly
assessed. This represents a major knowledge gap, because suscepti-
bility to hepatic IRI is known to increase with age.9,10 In consider-
ation of an aging population and a growing demand for surgery on
elderly liver,11,12 a clear need exists to establish measures that protect
old liver against IR.
The most common surgical techniques nowadays applied in the
clinic to lessen IRI are ischemic preconditioning (IPC) and intermittent
clamping (IC).5–8 For IPC, liver is exposed to brief episodes of IR via
clamping of the portal triad before the actual long ischemia time, as to
prepare liver for the imminent hypoxic insult.13 IPC clamping either
may consist of several repetitive periods or is done for one continuous
period.8,14 Of note, although continuous IPC has been found to
markedly reduce IRI in young mice, it appears to lose this effect in
aged liver under both experimental and clinical settings.9,15
For IC, the actual ischemic period is interrupted by brief
episodes of reperfusion; thus, the protective measure is integral to the
surgical operation. IC efficiently protects youngmouse liver from IRI
and has been shown to outperform IPC particularly in settings of
prolonged ischemia.13 In the clinic, IC is hence considered the gold
standard for ischemic hepatoprotection.16Whether IC can protect old
liver remains unclear.
Recently, a novel preconditioning approach has attracted
considerable interest. Remote IPC (RIPC) differs from other (pre)-
conditioning strategies in that it is performed distant from the
surgical site, omitting stress on the target organ. Brief episodes of
ischemia with intermittent reperfusion are introduced at, for
example, a limb, leading to systemic protection against subsequent
insults as evinced on kidney, heart, liver, and other tissues.17 We have
recently identified a general mechanism that underlies the systemic
protection conferred through RIPC18; remote blood occlusion leads
to serotonin release from platelets, which stimulates endothelial Vegf
secretion to upregulate in target organs Il10 and Mmp8, acting in
concert for protection. Interrupting this serotonin-Vegf-Il10/Mmp8
axis at any point renders RIPC inefficient in protecting against
hepatic IR.18 Whether RIPC can likewise protect old liver is unclear.
However, we have shown that Vegf administration is able to restore
the diminished regenerative capacity of old liver to levels seen in
young animals.10 Therefore, the beneficial effects of RIPC may
extend to the protection from hepatic IRI in the elderly.
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Here, we sought to estimate the utility of RIPC as a precon-
ditioning approach for the aging liver patient. First, we compared the
hepatoprotective effects of RIPC with IPC (both repetitive and
continuous) and the gold standard IC in old mouse liver exposed
to IR. Further to this, we assessed whether hepatoprotection through
RIPCmay rely on its capacity to induce systemic Vegf elevations and
associated changes in protective signaling and vascular integrity.
METHODS
Animals
C57Bl/6mice (Harlan, Netherlands) aged 20 to 24months were
kept on a 12-hour day/night cycle with free access to food and water.
All animal experiments were in accordance with Swiss federal animal
regulations and approved by the cantonal veterinary office of Zurich.
Animal Surgery and Treatment
IPC and IC were performed as previously reported
(Fig. 1A).14,19 RIPC was done by clamping the femoral vascular
bundle just proximal to its confluence with the femoral nerve as
described (Fig. 1B).18 For IR, an established model of 1-hour 70%
hepatic ischemia was used.18 Neutralizing Vegf antibody (4mg/kg, or
unspecific IgG for controls; R&D Systems, Abingdon UK) was
intravenously (i.v.) injected 1 hour before RIPC.
Histological Examination, Immunohistochemistry,
and Electron Microscopy
Hematoxylline-eosine staining was performed on 3mm
archived sections. Electron microscopy was performed as reported.10
Histological analyses were performed in a blinded fashion.
Biochemical Analysis of Enzyme Activity
Serum alanine aminotransferase (ALT)/aspartate aminotrans-
ferase (AST) levels were measured with a biochemical analyzer
(Ektachem DTSCII; Johnson & Johnson Inc., Rochester, NY).
Transcript Analysis With Quantitative Real-time
Polymerase Chain Reaction
Total RNA was extracted from 50mg tissue using Trizol
reagent (Invitrogen, Basel CH, Switzerland). Quantitative real-time
polymerase chain reaction (PCR) was performed on cDNA (Thermo-
Script reverse-transcription PCR System; Invitrogen) using an ABI
Prism 7500 Sequence Detector System (PE Applied Biosystems,
Rotkreuz CH, Switzerland). Primers are listed in Suppl. Table 1,
http://links.lww.com/SLA/B17. The results represent mean fold
induction of mRNA expressionSD.
ELISA
Serotonin (BA E-5900; Rocky Mountain Diagnostics Inc,
Colorado Springs, CO), Hmgb1 (ST51011; IBL International, Ham-
burg, Germany), and Vegf (DY493; R&D Systems, Minneapolis,
MN) levels were measured in triplicates by enzyme-linked immu-
nosorbent assay (ELISA).
Statistical Analysis
GraphPad Prism (GraphPad Software, Inc., La Jolla, CA) was
used. Groups were compared with a t test or 1-way analysis of
variance (ANOVA) with posthoc Bonferroni correction where appro-
priate. P < 0.05 was considered significant. MeanSD is shown.
Six animals/group were analyzed unless otherwise stated.
RESULTS
The experimental set up is summarized in Fig. 1A and
compares RIPC with IC, IPC, and sham proper controls for both
RIPC and IPC, followed by 1 hour of 70% hepatic ischemia. Each
procedure was performed in mice aged 20 to 24 months. Survival for
all experimental arms was 100%, enabling the analysis of all animals.
RIPC is Superior in Protecting Old Liver From
Ischemic Insults
To determine which of the preconditioning approaches best
protects aged liver against IRI, we measured several injury-related
parameters at 6 hours following reperfusion. Compared with sham
procedures, IPC was ineffective in reducing the hepatic injury
markers AST and ALT (Fig. 2A), necrotic liver area (Fig. 2B),
and serum Hmgb1 levels, a generic marker of necrotic cell death
(Fig. 2C). IPC with repetitive ischemia performed slightly better than
continuous IPC, but remained without significant effects (Fig. 2A–
C). In contrast, IC lowered all injury parameters following reperfu-
sion, particularly Hmgb1 (Fig. 2A–C). RIPC, on the contrary,
FIGURE 1. Experimental set up for comparing RIPC with other
protective measures. A, Design of experimental procedure.
IPC-15 continuous IPC, IPC-3 x5 repetitive IPC. Save for IC,
these procedures comprised the same total exposure to ische-
mic and reperfusion periods. IC comprised a shorter total
ischemic exposure (60 vs 75min) due to its intrinsic design.
Sham operations included all steps of either RIPC or IPC apart
from vessel clamping. Control animals were not manipulated
and served to retrieve baseline values for injury markers. Tissue/
serum was analyzed either 6h after reperfusion to assess IRI, or
immediately after preconditioning to assess direct effects. For
all experimental arms, 6mice/group were used. B, Intraoper-
ative situs for RIPC. FA indicates femoral artery; FN, femoral
nerve; FV, femoral vein.
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outperformed all other procedures, compared with these, including IC.
RIPC significantly reduced serum AST/ALT, necrotic area on
histology, and serumHmgb1 (Fig. 2A–C). Therefore, among the tested
procedures,RIPC is themost effective inprotecting aged liver fromIRI.
RIPC is Superior in Promoting Protective Signaling
We have previously shown that the RIPC-conferred protection
relies on the activation of the serotonin-Vegf-Il10/Mmp8 axis.18 To
determine whether this axis may contribute to the beneficial effects
of RIPC in old liver, we assessed the levels of these molecules
immediately after performing preconditioning, that is, before reper-
fusion. Likewise, we assessed serum Hmgb1, because lowering pre-
reperfusion Hmgb1 levels is strongly protective in IRI.20 Further-
more, we measured markers of Kupffer cell polarization, as an
M1>M2 polarization shift can mitigate IRI.21 No measurements
were done for IC, as this technique does not include a defined pre-
reperfusion period.
Compared with IPC, RIPC induced the highest elevations in
serum serotonin and Vegf while markedly reducing Hmgb1 levels
(Fig. 3A–C). Indeed, the IPC approaches were statistically indis-
tinguishable from sham controls for serotonin and Vegf, but associ-
ated with clear elevations in Hmgb1 (Fig. 3A–C), known to be a key
mediator of ischemic injury following reperfusion.20 Moreover,
although all measures led to Mmp8 induction, Il10 was most potently
induced by RIPC (Fig. 3D, to the right). When ranked Il10 andMmp8
expression data were combined into 1 value, RIPC induced the
highest Il10/Mmp8 score (mean  SD: 16.96  2.1 for RIPC,
8.86  2.26 for IPC-3 15, 8.42 2.31 for IPC-15, P < 0.001).
Therefore, only RIPC will lead to full Il10/Mmp8-mediated protec-
tion, as neither Il10 nor Mmp8 alone is sufficient to lessen IRI.18
Finally, RIPC markedly reduced the gene expression of M1 polar-
ization markers Emr1, Cd40, Nos2a, and Il12a (associated with
proinflammatory Kupffer cell activity), whereas the IPC approaches
had a little effect. Some improvement, particularly with intermittent
IPC, was noted for the M2 markers Arg, Clec10a, and Mrc1;
however, this was modest compared with RIPC (Fig. 3D). We
conclude that RIPC is superior over IPC in inducing the seroto-
nin-Vegf-Il10/Mmp8 axis, in reducing Hmgb1 levels, and in promot-
ing M2 Kupffer cell polarization, all molecular events that are
associated with protection from IRI.
Vegf is a Key Mediator of Protective RIPC Effects in
Old Liver
In young animals, Vegf is central for the conversion of RIPC
stimuli into systemic protection.18 To define the role of Vegf in the
RIPC effects on old liver, we pretreated aged mice with neutralizing
aVegf antibody before RIPC, leading to pre-reperfusion Vegf levels
akin to sham controls (Fig. 4A). Antibody pretreatment further led to
an increase in Hmgb1 (Fig. 4A) to levels observed after IPC (Fig. 3A).
Moreover, aVegf treatment prevented the RIPC-induced downregu-
lation ofM1-associatedgenes.Viceversa,M2markerswere dampened
to levels seen after IPC, as were the elevations in Il10 expression
(Figs. 3B and 4A). Mmp8, which was similarly induced by all
preconditioning approaches (Fig. 3B), was not affected by aVegf
pretreatment (Fig. 4A). Nonetheless, aVegf significantly (P ¼ 0.02)
reduced combined Il10/Mmp8 scores relative to RIPC alone
(mean SD: 12.6 2.07 forRIPC andaVegf, 17.06 2.51 forRIPC).
To define whether aVegf-induced changes in pre-reperfusion
signaling translate into an abrogation of RIPC-induced protection,
we treated mice with aVegf antibody, performed RIPC followed by
1 hour ischemia, and assessed injury 6 hours after reperfusion. Upon
aVegf treatment, RIPC lost all its protective effects, resulting in IRI
as seen in sham controls (Fig. 4B). We conclude that Vegf is a central
mediator of the protective effects RIPC has on old liver.
RIPC Mitigates Age-related Deficiencies in Hepatic
Sinusoids
Liver sinusoids feature highly differentiated endothelium
typified through fenestration. Sinusoidal fenestration is known to
disappear with age and negatively impacts liver function.22 We
performed RIPC on old mice and prepared liver immediately after
the last RIPC cycle for electron microscopy. Although liver of sham-
treated mice had typical signs of pseudocapillarization, fenestration
in sinusoids of RIPC-treated mice was enlarged and more regular
(Fig. 5). Therefore, RIPC mitigates the age-related dedifferentiation
of hepatic sinusoids.
DISCUSSION
In this study, we demonstrate that RIPC is an effective strategy
to protect old mouse liver from ischemic injury. Indeed, RIPC
FIGURE 2. IRI levels at 6 h postreperfusion following (pre)con-
ditioning. A, Serum AST, ALT. B, Necrotic area. C, Serum
Hmgb1.
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performs even better than IC, the current gold standard in the clinic.
The superior effects of RIPC are dependent on its ability to induce
systemic elevations in Vegf, which in turn activates hepato-protective
signaling in liver.
To define the protective capacities of RIPC, we compared with
several surgical approaches that are being used in patients to reduce
postoperative complications resulting from IR exposure. Liver injury
was assessed by multiple parameters at 6 hours postreperfusion, a
time point that we have previously found to reliably reflect injury
levels present also later after reperfusion.18 On all measures, RIPC
outperformed IC, while the IPC approaches failed to confer protec-
tion on aged liver and were even counterproductive on measures such
as Hmgb1, consistent with a previous study.9
RIPC alone induced the highest rise in the serotonin-Vegf axis
compared with the other approaches. Neutralizing Vegf antibody
abolished the RIPC effects, indicating a key role for Vegf in the
protection of old liver, and consistent with Vegf as a mediator of
systemic RIPC effects.18 Vegf antibody alsomarkedly diminished the
RIPC-induced changes in M1/M2 polarization markers, suggesting
that anti-inflammatory M2 polarization of Kupffer cells contributes
to the protection against IR. These effects are akin to those of V3-
fatty acids, wherein protection from hepatic IRI is associated with a
shift to M2 polarization.21 Likewise, Vegf inhibition suppressed the
RIPC-induced elevations in Il10, but not those in Mmp8, two
important components of the protective serotonin-Vegf axis.18 In
keeping, Mmp8, but not Il10, was induced by the ineffective IPC
approaches, confirming that upregulation of both molecules is
needed for protection.18 On the basis of these data, we propose that
circulating Vegf primes old liver against harm likely by shifting
Kupffer cells toward an anti-inflammatory repair phenotype.
In addition, Vegf promotes the expression of cytoprotective Il10,
which – despite being a typical M2 macrophage molecule – is also
strongly expressed in hepatocytes after RIPC, wherein its acts in
concert with Mmp8 to protect the parenchyme.18
RIPC further improved the age-related decline in sinusoidal
fenestration. Interestingly, Vegf signaling is required to maintain full
fenestration in rat sinusoids, and we have previously shown that
serotonin-Vegf signaling improves fenestration in old liver.10,23 Of
note, fenestration reopening correlated with an improvement of the
diminished regenerative capacity of old liver.10 Given that recovery
from ischemic insults requires parenchymal regeneration, RIPC
might hence reduce ischemic injury by promoting hepatocyte regen-
eration via a mechanism dependent on Vegf, consistent with the key
regenerative role of Vegf after hepatectomy.24 Further work is
required to demonstrate an effect of RIPC on liver regeneration;
however, preliminary data from our laboratory suggest that RIPC
does promote regeneration after resection.
RIPC likewise elicits a number of other, Vegf-independent,
mechanisms that contribute to its beneficial effects, including proc-
esses beyond purely ischemic insults.25 Although the latter effects
are systemic and may affect virtually any organ,17,18,26 other benefits
of RIPC may extend to processes such as fracture healing, fibrotic
prevention, acute mountain sickness, exercise performance, or pan-
creatitis.18,27–30 On the contrary, the variety of potential action
mechanisms may pose limits to the clinical application of RIPC.
Commonly used anesthetics/analgesics (eg. propofol, fluranes,
FIGURE 3. Direct effects immediately
following (pre)conditioning. A, Effects
on circulating serotonin, Vegf, and
Hmgb1. B, effects on Kupffer celll polar-
ization markers (M1: Emr1, Cd40, Nos2a,
Il12a: M2: Arg1, Clec10a, Il10) and cyto-
protective molecules (Il10, Mmp8). P <
0.05. ns indicates nonsignificant.
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opioids) seem to interfere with the effects of preconditioning, either
by counteracting or mimicking protective mechanisms.31–33 Two
major trials on RIPC for cardiac surgery surprisingly concluded with
the absence of benefits for patients.34,35 Although many reasons may
come into play, a plausible explanation for failed protection through
RIPC is that the pharmacological agents used in these 2 trials have
neutralized any RIPC benefits or have pre-engaged protective routes
otherwise activated through RIPC.33 Therefore, knowledge of the
FIGURE 4. Effects of aVegf pretreatment on RIPC-
induced molecular changes and protection. A,
Immediate effects on circulating Vegf, Hmgb1
(upper panels), macrophage polarization markers,
and cytoprotective molecules (lower panel) follow-
ing RIPC. B, Effects on liver injury parameters at 6 h
after reperfusion subsequent to RIPC. P < 0.05. ns
indicates nonsignificant.
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molecular paths that transmit and implement the many effects of
RIPC is needed to define the clinical circumstances amenable to
RIPC-conferred protection. In this regard, the serotonin-Vegf axis,
clearly a key pathway of RIPC, may provide molecular markers (eg.
circulating Vegf) to estimate whether, for example, specific anes-
thetics are suitable for a combination with RIPC.
Surgery on aged liver may be associated with additional factors
limiting the application of RIPC. The incidence of chronic liver
diseases such as fibrosis or hepatitis increases with age, and how
these affect the efficacy of RIPC is largely unknown. For example, the
increased angiogenic activity ongoing with liver fibrosis may interfere
with Vegf-dependent protection induced by RIPC36; liver tumors,
prime indications for surgery, on their own can produce significant
amounts of Vegf and could mask beneficial RIPC effects. Indeed,
direct Vegf injectionmay be used instead of RIPC, aswe demonstrated
for young mice.18 However, RIPC-induced Vegf elevations are likely
more subtle and short-lived than a direct injection andhencemaybear a
smaller risk with regard to promotion of tumor-associated vasculature.
Moreover, Vegf injection would not activate Vegf-independent path-
ways that may contribute to protection. These and related issues need
to be experimentally addressed as to identify conditionswhereinRIPC,
or Vegf as a substitute, can unfold its powers. On the basis of our
preclinical findings, we have initiated a clinical trial evaluating the
effects of RIPC on morbidity and mortality post gastrointestinal and
liver surgery (NCT02375269). Subanalyses should reveal which path-
ologies appear compatible with RIPC and whether RIPC indeed is
protective also in the elderly.
In conclusion, our findings demonstrate the preclinical effi-
cacy of RIPC in protecting old liver against IR. The effects RIPC
imparts on old liver are chiefly mediated by circulating Vegf,
resulting in the upregulation of cytoprotective molecules in liver,
the promotion of an anti-inflammatory Kupffer cell phenotype, and
an improved sinusoidal differentiation. The ease of its application in
the clinic, the sparing of the target organ, and the large variety of
potential beneficial effects render RIPC a highly attractive strategy
for the reduction of postoperative complications. Particularly in the
light of future demographics, our results advocate for a rapid
evaluation of RIPC in liver surgery.
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DISCUSSANTS
X. Rogiers (Gent, Belgium):
I would like to congratulate you as well as your co-investi-
gators on this fine piece of experimental work. In this work, you
demonstrate the preclinical efficacy of remote ischemic precondi-
tioning (RIPC) in protecting old livers against ischemia reperfusion
injury (IR) in a mice model.
My first question relates to age. Is there strong evidence that
age-dependent problems with recovery from IR are also present in
humans and what is the critical age? Your mice are 20 to 24months of
age. What age in humans would that relate to?
Damage by chemotherapy may be more relevant than age
for the liver. Can you speculate if this works in chemotherapy-
damaged livers?
My other question is whether it is the age of the liver or the age
of the patient, which is relevant. This might have importance in the
transplantation setting where the median donor age is steadily
increasing and may impact on graft quality. Could you speculate
on the importance of your work for the transplantation patients?
Response From P. Limani (Zurich, Switzerland):
Thank you for your kind comments and relevant questions.
There is good evidence in humans for ischemic injury increas-
ing with age [Transplant Proc 1995;27:1181-3. and Dig Dis Sci
2016;61:626-35]. We further showed that ischemic preconditioning
loses its effects in patients above 65 years, suggesting this is a critical
age (Ann Surg 2006;244:921-8).
As for mouse age, 20 months correspond to about 80 years
in humans.
How RIPC would affect injury levels in chemotherapy-dam-
aged livers is difficult to predict. Oxaliplatin-based regimens often
infer sinusoidal injury. In our study, RIPC improved sinusoidal
integrity, it hence is tempting to speculate that RIPC might be of
benefit here. Our preliminary findings further indicate RIPC does
improve the regenerative capacity of liver, perhaps aiding the recov-
ery of chemically damaged parenchyme as well.
Finally, while RIPC and Vegf may also affect the patient body,
we observed a direct, protection-associated effect on age-related
pseudocapillarization in liver. As we have previously shown, Vegf
induction and reversal of pseudocapillarization also improve the
regenerative capacity of aged liver [PNAS USA 2011;108:2945-50].
These hepatic effects should be beneficial for the transplantation of
old grafts obtained from old donors.
A. Pinna (Bologna, Italy):
Have you given a thought to infused plasma from remote
ischemia preconditioning animals to control animals?
What do you think about infusing ischemic protective cyto-
kines in IR animals to see if there is a difference in the damage?
Response From P. Limani (Zurich, Switzerland):
Thank you for this question. Indeed, we have not studied RIPC
plasma, but this is an interesting thought. Wewould expect that RIPC
plasma is likewise protective. Whereas circulating Vegf clearly is
crucial for protection, it is likely other factors contribute. This could
be researched with plasma experiments. For example, if whole
plasma is more protective, additional protective molecules such as
cytokines should be present. Likewise, the latter would be the case if
RIPC plasma from animals pretreated with an anti-Vegf antibody still
confers some protection. Such plasma then could be systematically
screened for candidate molecules such as cytokines.
T. van Gulik (Amsterdam, The Netherlands):
This RIPC strategy is a fascinating phenomenon. You very
nicely demonstrated morphologically with scanning electron micro-
scopy the fenestrations of the sinuosoidal endothelial cells showing
defects as a result of postischemic reperfusion. We know that in
particular it is the space of Disse behind the endothelial cells that is
injured. Did you look with transmission electron microscopy at the
sinusoidal endothelial cell lining to observe these spaces of Disse
behind the endothelial cells that is injured?
Your hypothesis is that you improved perfusion of the liver by
RIPC. Did this translate into decreased portal pressure? The endpoint
is portal pressure which will increase when there is endothelial injury
and which will decrease if you improve microcirculation of the liver?
Response From P. Limani (Zurich, Switzerland):
Thank you for your important comments and questions. We
did not examine the space of Disse, because our study focused on
pseudocapillarization of the sinusoids. We hence examined liver only
by scanning EM. Clearly, the space of Disse, likely also affected by
aging, should be considered in future studies on RIPC and old liver.
RIPC is known to improve hepatic microcirculation, and
dilated fenestration has been associated with reduced portal pressure.
We therefore expect that RIPC, opening fenestrae, will also reduce
portal pressure. We have not investigated this further, but we agree
that portal assessment would be important in establishing the
above associations.
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